42C Stock Overview
A specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
iX Biopharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.035 |
| 52 Week High | S$0.099 |
| 52 Week Low | S$0.033 |
| Beta | 0.95 |
| 1 Month Change | -25.53% |
| 3 Month Change | -22.22% |
| 1 Year Change | -61.11% |
| 3 Year Change | -85.71% |
| 5 Year Change | -84.09% |
| Change since IPO | -93.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| 42C | SG Pharmaceuticals | SG Market | |
|---|---|---|---|
| 7D | -10.3% | -0.6% | 0.4% |
| 1Y | -61.1% | 1.9% | 0.9% |
Return vs Industry: 42C underperformed the SG Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: 42C underperformed the SG Market which returned 0.9% over the past year.
Price Volatility
| 42C volatility | |
|---|---|
| 42C Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in SG Market | 14.6% |
| 10% least volatile stocks in SG Market | 2.2% |
Stable Share Price: 42C's share price has been volatile over the past 3 months.
Volatility Over Time: 42C's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of SG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | Eddy Lee | www.ixbiopharma.com |
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, Europe, the United States, China, and Australia. The company operates through Pharmaceutical and Nutraceutical segments. It offers Wafermine, a sublingual ketamine wafer, which has completed phase-2 clinical trial for the treatment of acute moderate to severe pain and complex regional pain syndrome; Xativa, a sublingual cannabidiol wafer, as well as Hypera, a tetrahydrocannabinol sublingual wafer for the treatment of anxiety, chronic pain, inflammation, and insomnia; and Wafesil and Silcap for the treatment of male erectile dysfunction.
iX Biopharma Ltd. Fundamentals Summary
| 42C fundamental statistics | |
|---|---|
| Market cap | S$26.89m |
| Earnings (TTM) | -S$9.59m |
| Revenue (TTM) | S$6.06m |
4.4x
P/S Ratio-2.8x
P/E RatioIs 42C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 42C income statement (TTM) | |
|---|---|
| Revenue | S$6.06m |
| Cost of Revenue | S$4.04m |
| Gross Profit | S$2.02m |
| Other Expenses | S$11.62m |
| Earnings | -S$9.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 33.37% |
| Net Profit Margin | -158.41% |
| Debt/Equity Ratio | 68.7% |
How did 42C perform over the long term?
See historical performance and comparison